Sort
23,748 grants matching “melanoma”
Development of Mouse and Humanized Models to Study Sex Disparities in Tumor Progression and Treatment of NSCLC
$172,376Joseph William Landry · Virginia Commonwealth University · R21 · FY2024 · CA
Evaluation of PAK inhibitors towards targeting adaptive mechanisms of resistance in high-risk rhabdomyosarcoma
$172,369Jason Yustein · Baylor College Of Medicine · R21 · FY2019 · CA
Online Advertising for Skin Cancer Prevention
$172,369Eleni Linos · University Of California, San Francisco · R21 · FY2018 · CA
Improving adoptive cell therapy by enhancing T cell longevity
$172,369Claudia Marcela Diaz-Montero · Cleveland Clinic Lerner Com-Cwru · R21 · FY2016 · CA
Proteomics of Metastatic and Non-Metastatic Uveal Melanoma
$172,369John W Crabb · Cleveland Clinic Lerner Com-Cwru · R21 · FY2018 · CA
Hyperpolarized arginine imaging of inflammatory cells and their inhibition in GBM
$172,369Sabrina Miriam Ronen · University Of California, San Francisco · R21 · FY2017 · CA
REVEALING SPATIAL TRANSCRIPTOMIC AND PROTEOMIC SHIFTS IN TUMOR-INFILTRATING IMMUNOCYTES: CHARTING A PATH TO ENHANCED MELANOMA THERAPEUTICS
$172,355University Of Connecticut Health Center · · FY2025 · Defense Health Agency
Biogenesis of Melanosomes
$172,288Seth J. Orlow · New York University School Of Medicine · R01 · FY2013 · AR
A systematic dissection of oncogenic KRAS signaling for target identification and therapeutic development
$172,260Tina Yuan · Dana-Farber Cancer Inst · K99 · FY2015 · CA
A systematic dissection of oncogenic KRAS signaling for target identification and therapeutic development
$172,260Tina Yuan · Dana-Farber Cancer Inst · K99 · FY2016 · CA
Biostatistics
$172,203Michael Joseph Schell · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2013 · CA
Detection of Melanoma by Canine Olfactory Receptors.
$172,125Tatjana Abaffy · University Of Miami School Of Medicine · R21 · FY2009 · CA
Regulatory Role of Mitochondrial DNA in Bladder Cancer Progression
$172,098John A Taylor · University Of Kansas Medical Center · R21 · FY2024 · CA
Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas
$172,052Kellen Leonard Olszewski · Kadmon Corporation, Llc · R43 · FY2014 · CA
Molecular Genetics of Melanoma
$172,041Hensin Tsao · Massachusetts General Hospital · K24 · FY2016 · CA
Improving Symptom Management for Survivors of Young Adult Cancer
$172,035Caroline Dorfman · Duke University · K08 · FY2019 · CA
Improving Symptom Management for Survivors of Young Adult Cancer
$172,021Caroline Dorfman · Duke University · K08 · FY2021 · CA
Improving Symptom Management for Survivors of Young Adult Cancer
$172,006Caroline Dorfman · Duke University · K08 · FY2020 · CA
Defining driver tumor-suppressors for melanoma using the zebrafish
$171,990Julien Ablain · Boston Children'S Hospital · K99 · FY2017 · CA
Defining driver tumor-suppressors for melanoma using the zebrafish
$171,990Julien Ablain · Boston Children'S Hospital · K99 · FY2016 · CA
Target metabolic vulnerabilities of MDSCs to enhance cancer immunotherapy
$171,932Bin Zheng · Massachusetts General Hospital · R21 · FY2020 · CA
Therapeutic use of immunomodulators and ionizining radiation
$171,928Karl Haglund · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
PQ3: Age-related immune deviation and cancer outcome
$171,825Holden T. Maecker · Stanford University · R21 · FY2016 · CA
Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas
$171,825Michael J Weber · University Of Virginia · R21 · FY2015 · CA
Cell Biology Core
$171,815Meenhard Herlyn · Wistar Institute · P01 · FY2009 · CA